Negative Ultraselection of Patients With
Journal
JCO precision oncology
ISSN: 2473-4284
Titre abrégé: JCO Precis Oncol
Pays: United States
ID NLM: 101705370
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
entrez:
11
5
2022
pubmed:
12
5
2022
medline:
18
5
2022
Statut:
ppublish
Résumé
Several uncommon genomic alterations beyond A prospective data set at three Italian Academic Hospitals included 650 patients with mCRC with comprehensive genomic profiling by FoundationOne CDx and treated with anti-EGFRs. PRESSING2 panel alterations were selected on the basis of previous clinico-biologic studies and included Among 162 hyperselected patients, 24 (15%) had PRESSING2 alterations, which were mutually exclusive except in two samples and were numerically higher in right-sided versus left-sided cancers (28% Negative ultraselection warrants further investigation with the aim of maximizing the benefit of EGFR blockade strategies in patients with
Identifiants
pubmed: 35544729
doi: 10.1200/PO.22.00037
pmc: PMC9200389
doi:
Substances chimiques
ErbB Receptors
EC 2.7.10.1
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2200037Commentaires et corrections
Type : ErratumIn
Références
Transl Lung Cancer Res. 2017 Oct;6(5):550-559
pubmed: 29114471
J Clin Oncol. 2019 Aug 1;37(22):1876-1885
pubmed: 31042420
Ann Oncol. 2017 Dec 01;28(12):3009-3014
pubmed: 29045518
Ann Oncol. 2019 Nov 1;30(11):1796-1803
pubmed: 31868905
Nature. 2019 Feb;566(7745):E11-E12
pubmed: 30755741
J Clin Oncol. 2019 May 10;37(14):1217-1227
pubmed: 30865548
Oncogene. 2005 Nov 14;24(50):7455-64
pubmed: 16288292
Oncogene. 2022 Jan;41(2):260-267
pubmed: 34728807
Ann Oncol. 2017 Aug 1;28(8):2030-2031
pubmed: 28475674
Cancer Discov. 2016 Aug;6(8):838-851
pubmed: 27179038
J Natl Compr Canc Netw. 2018 Dec;16(12):1547-1548
pubmed: 30545999
J Transl Med. 2015 May 07;13:140
pubmed: 25943333
Br J Cancer. 2007 Oct 22;97(8):1139-45
pubmed: 17940504
Nat Rev Cancer. 2017 Feb;17(2):79-92
pubmed: 28050011
Mod Pathol. 2020 Dec;33(12):2397-2406
pubmed: 32483240
J Clin Oncol. 2010 Mar 1;28(7):1254-61
pubmed: 20100961
Cancer Med. 2020 Feb;9(3):1044-1057
pubmed: 31856410
Eur J Cancer. 2015 Jul;51(11):1405-14
pubmed: 25979833
Ann Oncol. 2018 Jan 1;29(1):44-70
pubmed: 29155929
Oncologist. 2011;16(1):53-60
pubmed: 21212430
Ann Oncol. 2015 Jan;26(1):13-21
pubmed: 25115304
Lancet Oncol. 2020 Oct;21(10):1353-1365
pubmed: 32919526
Front Oncol. 2018 Nov 08;8:474
pubmed: 30467535
Ann Oncol. 2014 Jul;25(7):1346-1355
pubmed: 24718886
Clin Cancer Res. 2013 May 1;19(9):2301-9
pubmed: 23406774
J Exp Clin Cancer Res. 2018 Jun 1;37(1):112
pubmed: 29859122
J Clin Oncol. 2019 Nov 20;37(33):3099-3110
pubmed: 31539295
Eur J Cancer. 2015 Mar;51(5):587-94
pubmed: 25673558
Ann Oncol. 2020 Nov;31(11):1491-1505
pubmed: 32853681
Cancer Cell. 2019 Jul 8;36(1):35-50.e9
pubmed: 31287991
Mol Oncol. 2014 Sep 12;8(6):1084-94
pubmed: 24913799
Cancer Discov. 2016 Jun;6(6):601-11
pubmed: 27102076
Int J Cancer. 2013 Sep 1;133(5):1259-65
pubmed: 23404247
JAMA Oncol. 2017 Feb 01;3(2):194-201
pubmed: 27722750
Eur J Cancer. 2015 Jul;51(10):1243-52
pubmed: 25937522
J Natl Cancer Inst. 2021 Nov 2;113(11):1561-1569
pubmed: 33825902
Oncologist. 2020 Jul;25(7):e1109-e1116
pubmed: 32272491
Nature. 2017 Aug 10;548(7666):234-238
pubmed: 28783719